Andrew Aromando

Ambrx Biopharma, Inc.Oncolytics Biotech Inc

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 1 buy · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€21k

▼ Sales (0 ops.)

—

Latest filing published 13 Feb 2026 for ONCOLYTICS BIOTECH INC, €21k. Read the official filing

Filing timeline

BuySale

Andrew Aromando

Insider track record

Disclosed buys

Disclosed sells

Signal history

No signal scores available.

Closed purchases

Market purchases

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

ONCOLYTICS BIOTECH INC 1 purchase · last 13 Feb 2026

Andrew Aromando: trading record in brief

Filings by Andrew Aromando span 2 companies, the busiest being Ambrx Biopharma, Inc. and Oncolytics Biotech Inc. We count 2 filings; the first trade dates from 11 December 2023 and the latest from 11 February 2026.

No open-market sale appears; the market trades are 1 purchase worth €21k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant. So far in 2026, the count stands at 1 purchase and no sales.

The record was last updated on 13 February 2026 with an open-market purchase (€21k) in Oncolytics Biotech Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.